115372 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39034)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22057)
  4. Surgery (21249)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15763)
  7. Center for Hematologic Malignancies (13263)
  8. Hematologic Malignancies, Division of (13087)
  9. Sloan Kettering Institute Postdocs (12936)
  10. Department of Pathology and Laboratory Medicine (12615)
Formats
  1. Journal Article (66748)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3743)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (661)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39034)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22057)
  4. Surgery (21249)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15763)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5599)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115372)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Radiation in a new era of multiple myeloma management: Patterns of utilization, clinical, radiologic, and biochemical outcomes, and possible genomic correlates of response
    Meeting Abstract

    Dreyfuss, A. D.; Fregonese, B.; Ma, J.; Reith, S.; Cederquist, G.; Hubbeling, H.; Tringale, K. R.; Wijetunga, N. A.; Usmani, S.; Hajj, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Five‐year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the Phase II L‐MIND study
    Meeting Abstract

    Duell, J.; Abrisqueta, P.; Andre, M.; Augustin, M.; Gaidano, G.; Barca, E. G.; Jurczak, W.; Kalakonda, N.; Liberati, A. M.; Maddocks, K. J.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Five‐year subgroup analysis of tafasitamab + lenalidomide from the phase II L‐MIND study in patients with relapsed or refractory diffuse large B‐cell lymphoma
    Meeting Abstract

    Duell, J.; Abrisqueta, P.; Dreyling, M.; Gaidano, G.; Barca, E. G.; Jurczak, W.; Maddocks, K. J.; Menne, T.; Nagy, Z.; Tournilhac, O.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Tafasitamab plus lenalidomide versus standard of care as second‐line (2L) therapy for patients with R/R DLBCL: A post hoc internal 2L analysis of L‐MIND (IN 2L‐MIND)
    Meeting Abstract

    Sehn, L. H.; Kuruvilla, J.; Salles, G.; Maddocks, K. J.; Koch, C.; Xue, Z.; Amoloja, T.; Amin, A.; Duell, J.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Patient‐ versus clinician‐reported symptoms in the POLARIX study
    Meeting Abstract

    Thompson, C. A.; Mehta‐Shah, N.; Flowers, C.; Salles, G.; Tilly, H.; Chua, N.; Casasnovas, R.; Miall, F.; Kim, T. M.; Tsai, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • The prognostic value of progressing within 24 months of frontline chemoimmunotherapy (POD24) in relapsed/refractory (R/R) follicular lymphoma (FL)—a SCHOLAR‐5 analysis
    Meeting Abstract

    Patel, A. R.; Limbrick‐Oldfield, E. H.; Kanters, S.; Ray, M. D.; Best, T.; Ghione, P.; Neelapu, S. S.; Gribben, J. G.; Beygi, S.; Bobillo, S.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Patterns of disease failure by response to induction therapy in a large cohort of patients with primary central nervous system lymphoma
    Meeting Abstract

    Tringale, K. R.; Yahalom, J.; Scordo, M.; White, C.; Zhang, Z.; Grommes, C.; Imber, B.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Evolving consolidation patterns and modern outcomes for a large longitudinal cohort of primary CNS lymphoma patients
    Meeting Abstract

    Imber, B. S.; Tringale, K.; White, C.; Zhang, Z.; Scordo, M.; Yahalom, J.; Grommes, C.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Radiotherapy as an effective bridge for chemo‐refractory or progressive secondary CNS lymphoma
    Meeting Abstract

    Cederquist, G.; Tringale, K.; Hajj, C.; Hubbeling, H.; Sarkar, R.; Ma, J.; Dreyfuss, A.; Fregonese, B.; Lee, J.; Salles, G.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Treatment outcomes of limited stage grade 3A follicular lymphoma
    Meeting Abstract

    Sarkar, R. R.; Lee, J.; Zhang, Z.; Zelenetz, A.; Salles, G.; Yahalom, J.; Imber, B.
    Hematological Oncology (2023)

    Fulltext@MSK | Save